Meridian Bioscience (VIVO)
Meridian Bioscience Liabilities: 17.49M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VIVO Liabilities Rankings
| Overall | 88th percentile | 507 of 4387 |
| Sector | 68th percentile | 161 of 506 in Healthcare |
| Industry | 47th percentile | 10 of 19 in Diagnostic Substances |
VIVO Liabilities Range, Past 5 Years
| Minimum | 11.90M | Jun 2010 |
| Maximum | 19.83M | Jun 2011 |
| Average | 16.80M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these VIVO related companies
VIVO News
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin
May 14, 2:20AM Benzinga
May 14, 2:20AM Benzinga
Meridian Bioscience, Inc. (VIVO) Declares $0.19 Quarterly Dividend; 4% Yield
Apr 26, 8:17AM Street Insider
Apr 26, 8:17AM Street Insider
Canaccord Genuity Reiterates a 'Buy' on Meridian Biosciences (VIVO); Positive Meeting With Management
Apr 16, 8:36AM Street Insider
Apr 16, 8:36AM Street Insider
Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26
Apr 12, 3:07PM Business Wire
Apr 12, 3:07PM Business Wire
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio
Mar 30, 5:16AM Benzinga
Mar 30, 5:16AM Benzinga
Meridian Bioscience (VIVO) Unit Gets TGA Clearance for Illumigene GBS Test
Mar 21, 7:05AM Street Insider
Mar 21, 7:05AM Street Insider
Canaccord Genuity Maintains a 'Buy' on Meridian Biosciences (VIVO); Illumigene Update
Mar 08, 9:02AM Street Insider
Mar 08, 9:02AM Street Insider
Meridian (VIVO) Unit Completes Manufacture of Human Rhinovirus Type 16
Feb 27, 7:01AM Street Insider
Feb 27, 7:01AM Street Insider
Meridian Life Science® Successfully Manufactures Rhinovirus Challenge Stock
Feb 27, 7:00AM Business Wire
Feb 27, 7:00AM Business Wire
Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis
Feb 16, 7:00AM Business Wire
Feb 16, 7:00AM Business Wire
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio
Feb 13, 5:07AM Benzinga
Feb 13, 5:07AM Benzinga
Raymond James Downgrades Meridian Biosciences (VIVO) to Market Perform
Feb 10, 2:18PM Street Insider
Feb 10, 2:18PM Street Insider
$VIVO could have bottomed out today and is heading towards its SMA at 19. With RSI of 33 and average financials still looks to be a rally.
about 122 days ago by AlphaoverBetaTrading
about 122 days ago by AlphaoverBetaTrading
$VIVO filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1XhK
about 171 days ago by MarketBrief
about 171 days ago by MarketBrief
Italy Has Finally Entered Our Markets (w/ Economic Calendar & Stock Radar) $DEJ $GST $AMCC $SPY $IWM $NR $VIVO $$ http://stks.co/16UL
about 201 days ago by MichaelKudrna
about 201 days ago by MichaelKudrna
The End of Dividend Growth at Meridian Bioscience? http://stks.co/14jb / $VIVO
about 205 days ago by DynamicDividend
about 205 days ago by DynamicDividend
A Strong Season For Trading (w/ Economic Calendar, Stock Radar & Jobs Report) $SPY $IWM $TRGT $VIVO $CSIQ $$ http://stks.co/zgA Please RT
about 208 days ago by MichaelKudrna
about 208 days ago by MichaelKudrna
$VIVO http://stks.co/xpM Over $18.67 on heavy volume could get this one moving!
about 211 days ago by Campagnatrading
about 211 days ago by Campagnatrading
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VIVO | 18.91 | -0.03 | -0.16% | 781.28M |
| VIV | 23.69 | +0.07 | +0.30% | 9.007B |
| VITC | 7.54 | -0.15 | -1.95% | 255.54M |
| VIT | 9.00 | -0.18 | -1.96% | 388.50M |
| VIST | 11.30 | -0.01 | -0.09% | 74.53M |
| VISN | 0.98 | +0.02 | +2.08% | 98.16M |
| VGR | 16.42 | -0.18 | -1.08% | 1.319B |
| VGEM | 18.07 | +0.00 | +0.00% | |
| VG | 1.71 | -0.12 | -6.56% | 412.90M |
| VFL | 13.79 | +0.13 | +0.95% |
